title: Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
authors: Davin
authors: D
authors: Quinn
authors: Elizabeth
authors: E
authors: Kuchler
authors: Paulina
authors: P
authors: Deming
authors: Sanjeev
authors: S
authors: Arora
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002389:Catatonia / Q000139:chemically induced* / Q000175:diagnosis; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b